Breast Cancer Program

项目摘要-乳腺癌计划 艾布拉姆森癌症中心(ACC)的乳腺癌项目(BCP)是一个高度 富有成效的研究人员专注于一个共同的目标：通过以下方式减少乳腺癌的负担和死亡率 阐明疾病的生物学机制并将这些知识转化为改进的 检测、预防和治疗。BCP成员高度协作，致力于 科学目标横跨从基础科学到临床研究的连续统一体。具体目标是：1)阐明 乳腺癌发生发展的生物学、遗传学和分子机制；2)进展 了解遗传易感性，以优化筛查和预防高危人群；3)制定 改进乳腺癌筛查、检测和生物标记物的创新成像方法以指导 治疗和评估治疗反应，以及4)将实验室发现转化为新的临床试验 治疗学，结合反应和结果的生物标记物。成员们取得了根本性的发现， 确定乳腺癌的驱动因素、肿瘤休眠和基因组完整性的机制、干扰素反应以及 辐射与免疫原性的关系。这些发现被转化为新的有针对性的 治疗，新的组合，基因组和预测分析，以及尖端成像方法和 探测器。计划成员设计和实施创新的临床试验，领导临床/翻译团队 在行政协调会内部、国家和国际范围内。在本供资期间，共有1386项应计项目 干预性试验和14,079项应计非干预性试验。程序的互补性 共同领导：Angela DeMichele，医学博士，MSCE(临床试验/生物标记物)和Roger Greenberg，医学博士，博士 (基础科学/遗传学)促进计划内和计划间的合作。用临床翻译的BASIC 以科学为主要着力点，扩大乳腺癌和遗传学的临床研究单位，增长和 管理大型生物标本银行，并招聘优秀的高级和初级教员。这些事态发展 在行政协调会试点基金的支持下，促进了新的想法和合作。PLS还发起了两个新的 基础科学中心、基因组完整性中心和马克基金会中心。该协会的25名成员 BCP来自七个大学系和两个学院，反映了不同的专业知识。BCP成员 持有1040万美元与癌症相关的赠款资金(年度直接成本)，其中660万美元用于同行审查，430万美元用于 是由NCI资助的。会员拥有26个R01或同等奖项(其中6个是多PI奖)，NCI R33月球射击 格兰特，以及国防部乳腺癌卓越中心。在当前的供资周期中，BCP成员 发表了403篇与癌症相关的论文，其中22%是计划内合作，37%是计划内合作 方案协作，72%是多机构性质的。得到高级临床领导的支持 在罗文乳房中心认可的国家乳房认证计划中，BCP产生 高影响力、改变实践的研究，推动乳腺癌治疗和结果的进步。

PROJECT SUMMARY – Breast Cancer Program The Breast Cancer Program (BCP) of the Abramson Cancer Center (ACC) is a multidisciplinary team of highly productive investigators focused on a common goal: to reduce the burden and mortality of breast cancer by elucidating biological mechanisms underlying the disease and translating this knowledge to improved detection, prevention and treatment. BCP members are highly collaborative, working on interconnected scientific aims that span the continuum from basic science to clinical research. Specific Aims are: 1) Elucidate the biologic, genetic and molecular mechanisms of breast cancer development and progression; 2) Advance understanding of genetic susceptibility to optimize screening and prevention for those at risk; 3) Develop innovative imaging approaches to improve breast cancer screening, detection and biomarkers to guide treatment and assess therapeutic response, and 4) Translate laboratory discoveries to clinical trials of novel therapeutics, incorporating biomarkers of response and outcome. Members made fundamental discoveries to identify breast cancer drivers, mechanisms of tumor dormancy and genome integrity, interferon response, and the relationship between radiation and immunogenicity. These findings were translated into new targeted therapeutics, novel combinations, genomic and predictive assays, and cutting-edge imaging methods and probes. Program members design and implement innovative clinical trials, leading clinical/translational teams within the ACC, nationally and internationally. In the current funding period, there were 1,386 accruals onto interventional trials and 14,079 accruals onto non-interventional trials. The complementary skills of Program co-Leaders (PLs) Angela DeMichele, MD, MSCE (clinical trials/biomarkers) and Roger Greenberg, MD, PhD (basic science/genetics) facilitate intra- and inter- Programmatic collaborations. With clinical translation of basic science as a major focus, the PLs expanded clinical research units for breast cancer and genetics, grew and curated large biospecimen banks, and recruited exceptional senior and junior faculty. These developments have fostered new ideas and collaborations supported by ACC pilot funds. The PLs also initiated two new basic science centers, the Center for Genome Integrity and the Mark Foundation Center. The 25 members of BCP come from seven University Departments and two Schools, reflecting diverse expertise. BCP members hold $10.4M in cancer-related grant funding (annual direct costs), of which $6.6M is peer-reviewed and $4.3M is NCI-funded. Members hold 26 R01s or equivalent (of which six are multi-PI awards), an NCI R33 Moonshot Grant, and a DOD Breast Cancer Center of Excellence. Over the current funding cycle, BCP members published 403 cancer-related papers, of which 22% were intra-Programmatic collaborations, 37% were inter- Programmatic collaborations, and 72% were multi-institutional in nature. Supported by senior clinical leaders within the National Accreditation Program for Breast Centers-accredited Rowan Breast Center, BCP generates high-impact, practice-changing research, moving the needle on breast cancer treatment and outcomes.